补肾生髓成肝方加减联合聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及对患者肝功能及肝纤维化的影响

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (565 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical efficacy of modified Bushen Shengsui Chenggan Preparation combined with pegylated interferon α-2b in the treatment of chronic hepatitis B (CHB) and its influence on liver function and liver fibrosis. Methods A total of 70 CHB patients in Hubei Hospital of Traditional Chinese Medicine from September 2017 to December 2019 were divided into the observation group（35 cases） and the control group（35 cases）by random number table method, the control group was treated with pegylated interferon α-2b, and the observation group was treated with modified Bushen Shengsui Chenggan Preparation combined with pegylated interferon α-2b, the traditional Chinese medicine symptom score, liver function index (serum total bilirubin [TBil], alanine aminotransferase [ALT], asparagine aminotransferase [AST], serum albumin [ALB]), liver fibrosis index (type Ⅲ procollagen [PCⅢ], collagen typeⅣ[Ⅳ-C], layer mucins [LN], hyaluronidase [HA]), HBV markers (ALT normalization rate, hepatitis B virus [HBV]-DNA negative conversion rate and Hepatitis B E antigen [HbeAg] negative conversion rate) before and after treatment and adverse reactions were compared between the two groups. Results Before treatment, there were no significant differences in traditional Chinese medicine symptom scores between the two groups (P ＞ 0.05); after treatment, traditional Chinese medicine symptom scores of the two groups were lower than before treatment, and the observation group was lower than the control group (P ＜ 0.05). Before treatment, there were no significant differences in liver function indexes (TBil, ALT, AST, ALB) between two groups (P ＞ 0.05); after treatment, the ALB levels of the two groups were higher than those before treatment, while the TBil, ALT, AST levels were lower than before treatment, and the ALB levels of the observation group were higher than the control group, while the TBil, ALT, and AST levels were lower than the control group (P ＜ 0.05). Before treatment, there was no significant difference in liver fibrosis indexes (PCⅢ, Ⅳ-C, LN, and HA) between the two groups (P ＞ 0.05). After treatment, the levels of PCⅢ, Ⅳ-C, LN, and HA in the two groups were lower than those before treatment, and the observation group was lower than the control group (P ＜ 0.05). After six month follow-up, the HBeAg negative conversion rate of the observation group was significantly higher than those of the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P ＞ 0.05). Conclusion Modified Bushen Shengsui Chenggan Preparation combined with pegylated interferon α-2b in the treatment of CHB is helpful to improve liver function and liver fibrosis. It has significant curative effect and good safety, and is worthy of clinical application.

Key words： Bushen Shengsui Chenggan Preparation Pegylated interferon α-2b Chronic hepatitis B Liver function Liver fibrosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Dawei1 LU Dingbo1 JIANG Shiyi1 LI Hanmin2

Cite this article:

HUANG Dawei1 LU Dingbo1 JIANG Shiyi1 LI Hanmin2. Clinical efficacy of modified Bushen Shengsui Chenggan Preparation combined with pegylated interferon α-2b in the treatment of chronic hepatitis B and its influence on liver function and liver fibrosis#br#[J]. 中国医药导报, 2021, 18(34): 86-90.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I34/86

[1] 陈小莉，栗文杰，赵俊彪，等.疏肝健脾方联合恩替卡韦治疗慢性乙型肝炎肝郁脾虚证临床研究[J].新中医，2020， 52（7）：77-79.
[2] 史娜，宋娟丽，王静，等.红外肝病治疗仪联合恩替卡韦及乙肝抗纤汤治疗老年慢性乙型肝炎的疗效[J].国际老年医学杂志，2020，41（5）：322-325.
[3] 张鑫，刘岩红，鉏曦，等.紫叶丹胶囊治疗恩替卡韦经治的HBeAg阳性慢性乙型肝炎患者的临床研究[J].中西医结合肝病杂志，2020，30（4）：292-295.
[4] 吴雄飞，方利娟，陈艳.替诺福韦联合干扰素-α治疗HBeAg阳性慢性乙型肝炎患者疗效及其血清细胞因子水平变化[J].实用肝脏病杂志，2020，23（5）：638-641.
[5] 王万娥，朱长权，李晶，等.化浊抗纤保肝汤治疗慢性乙型肝炎肝纤维化的临床研究[J].中国医院用药评价与分析，2020，20（10）：1189-1192.
[6] 中华医学会肝病学分会，中华医学会感染病学分会.《慢性乙型肝炎防治指南（2015更新版）[J].传染病信息，2015，28（6）：321-340.
[7] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：104-105.
[8] Zeng DW，Dong J，Liu YR，et al. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection [J]. World J Gastroenterol，2016，22（29）：6663-6672.
[9] 林扬，林翠英，王艳娇，等.扶正化瘀胶囊联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化临床研究[J].新中医，2021，53（6）：51-54.
[10] 钱倩宇，应娜，杨贞，等.丹参酮ⅡA通过激活PPARα减轻4-HNE诱导的肝细胞损伤的机制研究[J].中国中药杂志，2019，24（9）：1862-1868.
[11] 马红，徐小元.中华医学会肝病学分会第五次全国肝纤维化、肝硬化学术会议纪要[J].中华肝脏病杂志，2017， 25（1）：61-62.
[12] 王冰琼，孙亚朦，尤红，等.肝纤维化和肝硬化逆转的时代：现状与挑战[J].临床肝胆病杂志，2019，35（4）：705-708.
[13] Brunetto MR，Bonino F. Interferon therapy of chronic hepatitis B [J]. Intervirology，2014，57（3/4）：163-170.
[14] 周宇辰，胡承光，袁国盛，等.抗病毒联合抗肝纤维化治疗慢性乙型肝炎肝纤维化降低肝细胞癌发生：144周的前瞻性队列研究[J].南方医科大学学报，2019，39（6）：633-640.
[15] 韩中颖，祝峻峰.软肝化瘀方联合恩替卡韦对慢性乙型肝炎后肝纤维化患者肝功能及血清学指标的影响[J].现代中西医结合杂志，2021，30（9）：979-982.
[16] 郑志恒，李维筠，回振宇，等.聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J].实用肝脏病杂志，2021，24（1）：19-22.
[17] 覃武海，王芬，刘辉华，等.恩替卡韦联合棒柄花叶清肝胶囊治疗慢性乙型肝炎肝纤维化患者的临床效果[J].广西医学，2021，43（2）：193-196.
[18] 索成云，崔向青，李艳芬，等.恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝纤维化疗效观察[J].现代中西医结合杂志，2019，28（12）：1339-1342.
[19] 高翔，叶之华，戴玲，等.基于网络药理学探讨左归丸“补肾生髓成肝”的疗效机制[J].中西医结合肝病杂志，2018，28（2）：96-100.
[20] 董亚云，向阳.护肝片联合恩替卡韦对老年慢性乙型肝炎患者疗效观察及对内皮功能和肝纤维化的影响[J].中国老年学杂志，2019，39（20）：4990-4992.
[21] 董福昌，龙健灵，林丽卿，等.血清肝纤维化指标联合肝生化检测对乙肝患者肝纤维化的评估[J].沈阳医学院学报，2018，20（3）：224-226.
[22] Yin XR，Liu ZH，Liu J，et al. First line nucleos（t）ide analog monotherapy is more cost - effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China [J]. Chin Med J（Engl），2019， 132（19）：2315-2324.
[23] Blackard JT，Kwara A，Sherman KE，et al. In response to identifi-cation of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients [J]. J Hepatol，2019，168（19）：30418-30420.
[24] 兰少波，王建忠，李瀚旻，等.“补肾生髓成肝”联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎的临床研究[J].中西医结合肝病杂志，2014，24（4）：203-206.
[25] 戴玲，高翔，叶之华，等.基于真实世界研究“补肾生髓成肝”治疗乙型肝炎相关性肝衰竭的临床疗效[J].中西医结合肝病杂志，2018，28（6）：325-327，356.